Cryoport, Inc. (CYRX)
| Market Cap | 790.81M +143.8% |
| Revenue (ttm) | 182.94M +14.0% |
| Net Income | 71.74M |
| EPS | 1.43 |
| Shares Out | 50.40M |
| PE Ratio | 10.95 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,636,948 |
| Open | 15.22 |
| Previous Close | 15.25 |
| Day's Range | 15.02 - 15.85 |
| 52-Week Range | 5.31 - 15.85 |
| Beta | 1.75 |
| Analysts | Strong Buy |
| Price Target | 14.78 (-5.8%) |
| Earnings Date | May 4, 2026 |
About CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The comp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CYRX stock is "Strong Buy." The 12-month stock price target is $14.78, which is a decrease of -5.80% from the latest price.
News
Cryoport price target raised to $17 from $15 at KeyBanc
KeyBanc analyst Paul Knight raised the firm’s price target on Cryoport (CYRX) to $17 from $15 and keeps an Overweight rating on the shares. The firm believes the company’s revenue…
Cryoport price target raised to $15 from $13 at Needham
Needham raised the firm’s price target on Cryoport (CYRX) to $15 from $13 and keeps a Buy rating on the shares.
Cryoport price target raised to $17 from $15 at BTIG
BTIG raised the firm’s price target on Cryoport (CYRX) to $17 from $15 and keeps a Buy rating on the shares. The firm is citing the company’s Q1 earnings beat…
Cryoport price target raised to $12 from $11 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Cryoport (CYRX) to $12 from $11 and keeps a Buy rating on the shares. After what the firm calls “a…
Cryoport Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 16% year-over-year to $47.8M, with strong double-digit gains across both Life Sciences Services and Products. Full-year guidance was raised to $192–$196M, and positive adjusted EBITDA is expected in the second half, driven by robust demand and operational improvements.
Cryoport Slides: Q1 2026
Cryoport has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
Cryoport Earnings release: Q1 2026
Cryoport released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Cryoport Quarterly report: Q1 2026
Cryoport has published its Q1 2026 quarterly earnings report on May 4, 2026.
Cryoport reports Q1 EPS (25c), consensus (19c)
Reports Q1 revenue $47.8M, consensus $44.86M. Jerrell Shelton, CEO of Cryoport (CYRX), commented, “Cryoport delivered a strong start to 2026 with first-quarter revenue of $47.8 million, up 16% year-ov...
Cryoport Reports First Quarter 2026 Financial Results
First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT pr...
Cryoport Proxy statement: Proxy filing
Cryoport filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Cryoport Proxy statement: Proxy filing
Cryoport filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
NASHVILLE, Tenn., April 20, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for ...
Craig-Hallum bullish on Cryoport, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Cryoport (CYRX) with a Buy rating and $15 price target CryoPort is a specialized logistics provider serving the C> market. The firm believe...
Cryoport initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Cryoport (CYRX) with a Buy rating and $15 price target
Cryoport Earnings Call Transcript: Q4 2025
Full year 2025 revenue reached $176.2M, exceeding guidance, with strong growth in commercial cell and gene therapy and life sciences services. 2026 guidance is $190–$194M, with positive adjusted EBITDA expected in H2 2026.
Cryoport Annual report: Q4 2025
Cryoport has published its Q4 2025 annual report on March 3, 2026.
Cryoport Earnings release: Q4 2025
Cryoport released its Q4 2025 earnings on March 3, 2026, summarizing the period's financial results.
Cryoport Slides: Q4 2025
Cryoport has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 3, 2026.
Cryoport reports Q4 EPS (27c), consensus (21c)
Reports Q4 revenue $45.45M, consensus $42.92M. Jerrell Shelton, CEO of Cryoport (CYRX), commented, “2025 was a year of strong progress for Cryoport. We delivered full-year revenue of $176.2M, exceedin...
Cryoport sees FY26 revenue $190.0M-$194.0M, consensus $189.5M
16:11 EST Cryoport (CYRX) sees FY26 revenue $190.0M-$194.0M, consensus $189.5M
Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServic...
Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sci...
Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series
Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryop...
Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around th...